ChromaDex is among latest targets of FDA/FTC joint warnings identifying claims on websites as well as in social media posts that render products unapproved and misbranded drugs indicated to prevent or treat COVID-19.

Q3 net sales were up 18% and its net loss dropped $3m, the provider of Tru Niagen products containing Niagen, its proprietary form of nicotinamide riboside, reported five days before announcing Tru Niagen stick packs are available under the EX brand in Hong Kong exclusively at A.S. Watson Group’s stores and website.

In response to what it says was unexpected airing of ChromaDex' ongoing disputes with Elysium Health, CRN will require speakers at its events to submit materials its review. Chromadex says CRN asked for the type of presentation its chairman made while Elysium Health wasn’t surprised a ChromaDex executive would comment on the litigation.